Spinifex's AT2 receptor antagonist meets PHN endpoint

Spinifex Pharmaceuticals Pty. Ltd. (South Yarra, Australia) said EMA401 met the primary endpoint of reducing mean daily pain intensity score from baseline to week four vs. placebo in a Phase II trial ...